“I join ProBioGen with the ambition to evolve our marketing department into a customer-centric and data-oriented revenue driver and am personally proud to become part of the company’s mission to develop tomorrow’s medicines,” Windt said.
Dr Stork takes on the leadership of ProBioGen’s growing and globally active BD team, to expand its customer base and to build long-lasting relationships. The BD team’s goal is to promote ProBioGen’s premium technologies and services that enable efficient production of biologics in the field of proteins and viral vectors/cell and gene therapy. Dr Stork is an experienced manager with an extensive scientific knowledge. As the head of Intravacc’s BD team, he was responsible for overseeing the acquisition of service projects as well as out-licensing. Since receiving his PhD in molecular microbiology in 2006, he has been active in the pharmaceutical field for over 18 years.
“I’m passionate about bringing scientific ideas to the market and using my knowledge of the entire value chain to help customers and ultimately patients,” Dr Stork said.
Dr Lutz Hilbrich, Chief Executive Officer of ProBioGen and MiGenTra, commented: “These new appointments bring three highly qualified leaders with first class expertise in their fields, as well as a passion for engaging and leading teams. Our vision is a world where there is treatment for every disease. With our topnotch services and technologies, we strive to make this dream a reality by empowering our clients to succeed in developing cutting-edge drugs and vaccines. Driven by the strong demand for our offerings, we plan to grow in a sustainable manner, enabling us to assist more and more clients, and ultimately, improve the lives of more patients. This calls for maintaining the highest standards in our processes, technologies, and products.”